AUXAGEN, INC.

Company Information
Address AUXAGEN, INC.
7 PRICEWOODS
SAINT LOUIS, MO, -


Information

DUNS: 153650655

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A Novel TGF-β Receptor Antagonist to Treat Pulmonary Fibrosis

    Amount: $283,567.00

    DESCRIPTION provided by applicant Pulmonary fibrosis PF including idiopathic PF IPF is a group of progressive incurable lung diseases with high mortality rates PF is characterized by excess ...

    SBIRPhase I2016Department of Health and Human Services
  2. TGF-beta Antagonists for Accelerating Wound Healing

    Amount: $998,034.00

    DESCRIPTION (provided by applicant): Every year in the United States, gt1.25 million people suffer from burns, 6.5 million have chronic skin ulcers caused by pressure, venous stasis or diabetes mellit ...

    SBIRPhase II2010Department of Health and Human Services
  3. A Therapeutic Agent for Radiation-induced Lung Fibrosis

    Amount: $227,692.00

    DESCRIPTION (provided by applicant): Lung fibrosis, a group of incurable lung diseases with high mortality rates, is characterized by inflammatory cell infiltration, fibroblast proliferation, and exce ...

    SBIRPhase I2009Department of Health and Human Services
  4. Novel Therapeutic Agents for Diabetic Ulcers

    Amount: $182,189.00

    DESCRIPTION (provided by applicant): Diabetes mellitus afflicts 20.8 million people, or 7% of the population, in the United States. Fifteen percent, or 2.4 million people, will develop diabetic foot u ...

    STTRPhase I2008Department of Health and Human Services
  5. Novel Antagonists for Ameliorating Pulmonary Fibrosis

    Amount: $199,467.00

    DESCRIPTION (provided by applicant): Pulmonary fibrosis, a group of incurable lung diseases with high mortality rates, is characterized by inflammatory cell infiltration, fibroblast proliferation, and ...

    STTRPhase I2007Department of Health and Human Services
  6. TGF-Beta Antagonists for Accelerating Wound Healing

    Amount: $175,480.00

    DESCRIPTION (provided by applicant): Impaired or abnormal wound healing is a major health problem for elderly, diabetic, immunosuppressed, immobilized, burn-injured and keloid individuals. Every year ...

    SBIRPhase I2006Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government